Nardilysin-regulated scission mechanism activates polo-like kinase 3 to suppress the development of pancreatic cancer.
Jie FuJianhua LingChing-Fei LiChi-Lin TsaiWenjuan YinJunwei HouPing ChenYu CaoYa'an KangYichen SunXianghou XiaZhou JiangKenei FurukawaYu LuMin WuQian HuangJun YaoDavid H HawkeBih-Fang PanJun ZhaoJiaxing HuangHuamin WangE I Mustapha BahassiPeter J StambrookPeng HuangJason B FlemingAnirban MaitraJohn A TainerMien-Chie HungChunru LinPaul J ChiaoPublished in: Nature communications (2024)
Pancreatic ductal adenocarcinoma (PDAC) develops through step-wise genetic and molecular alterations including Kras mutation and inactivation of various apoptotic pathways. Here, we find that development of apoptotic resistance and metastasis of Kras G12D -driven PDAC in mice is accelerated by deleting Plk3, explaining the often-reduced Plk3 expression in human PDAC. Importantly, a 41-kDa Plk3 (p41Plk3) that contains the entire kinase domain at the N-terminus (1-353 aa) is activated by scission of the precursor p72Plk3 at Arg354 by metalloendopeptidase nardilysin (NRDC), and the resulting p32Plk3 C-terminal Polo-box domain (PBD) is removed by proteasome degradation, preventing the inhibition of p41Plk3 by PBD. We find that p41Plk3 is the activated form of Plk3 that regulates a feed-forward mechanism to promote apoptosis and suppress PDAC and metastasis. p41Plk3 phosphorylates c-Fos on Thr164, which in turn induces expression of Plk3 and pro-apoptotic genes. These findings uncover an NRDC-regulated post-translational mechanism that activates Plk3, establishing a prototypic regulation by scission mechanism.